Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort
- PMID: 28753864
- PMCID: PMC7061732
- DOI: 10.1016/j.euf.2017.02.016
Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort
Abstract
Background: ETS-related gene (ERG) oncogenic activation is the most common genomic alteration in prostate cancer (CaP) although it occurs less frequently in African American (AA) versus Caucasian (CA) patients, and the potential role of ERG as a prognostic marker has not been confirmed.
Objective: This study was conducted to confirm strong racial variation in the prevalence of ERG oncoprotein expression and to examine ERG oncoprotein expression, race, and body mass index as independent and joint predictors of CaP biochemical recurrence (BCR) following radical prostatectomy (RP).
Design, setting, and participants: A retrospective cohort study of CA and AA CaP patients enrolled at Walter Reed National Military Medical Center, who donated clinically annotated, whole-mounted, prostatectomy specimens between 1994 and 2014 following RP, was conducted.
Outcome measurements and statistical analysis: Kaplan-Meier (KM) estimation curves and multivariable Cox proportional hazards models were used to examine time to BCR as a function of ERG status, patient race, and obesity.
Results and limitations: Among 930 eligible patients (36.1% AA and 63.9% CA), with 155 (16.7%) BCR events and a median follow-up time of 5.1 yr, ERG oncoprotein expression was significantly less prevalent in index tumors of AA versus CA patients (23.2% vs 49.3%; p<0.0001). KM curves showed significantly poorer BCR-free survival for CA patients with ERG-negative index tumors but not for AA patients. Race-stratified multivariable analyses revealed a significant association between ERG-negative index tumors and poorer BCR-free survival among CA patients (hazards ratio=1.67, confidence interval=1.07, 2.61; p=0.024). Less heterogeneity in ERG expression among AA patients may reduce the ability to show its association with BCR.
Conclusions: Striking racial variation in ERG oncoprotein expression was confirmed. A novel observation was the importance of index tumor ERG-negative status in predicting CaP progression for CA patients.
Patient summary: ETS-related gene (ERG) typing of tumors may be useful in prognosticating prostate cancer aggressiveness.
Keywords: Biochemical recurrence; ERG fusion; Obesity; Prostate cancer; Race.
Copyright © 2017 European Association of Urology. All rights reserved.
Figures


Similar articles
-
Race, tumor location, and disease progression among low-risk prostate cancer patients.Cancer Med. 2020 Mar;9(6):2235-2242. doi: 10.1002/cam4.2864. Epub 2020 Jan 21. Cancer Med. 2020. PMID: 31965751 Free PMC article.
-
Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.BJU Int. 2013 Apr;111(4 Pt B):E186-90. doi: 10.1111/j.1464-410X.2012.11540.x. Epub 2012 Oct 26. BJU Int. 2013. PMID: 23107067
-
Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.Eur Urol. 2017 May;71(5):697-700. doi: 10.1016/j.eururo.2016.07.026. Epub 2016 Jul 28. Eur Urol. 2017. PMID: 27477529 Free PMC article.
-
Examining the Association between ERG/PTEN Expression and Biochemical Recurrence in Prostate Cancer: A Comprehensive Meta-Analysis.Arch Esp Urol. 2025 Jan;78(1):25-36. doi: 10.56434/j.arch.esp.urol.20257801.4. Arch Esp Urol. 2025. PMID: 39943631
-
The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.Dan Med J. 2016 Dec;63(12):B5319. Dan Med J. 2016. PMID: 27910803 Review.
Cited by
-
Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer.Cancer Med. 2023 Feb;12(4):4306-4320. doi: 10.1002/cam4.5301. Epub 2022 Nov 3. Cancer Med. 2023. PMID: 36329628 Free PMC article.
-
Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.Sci Rep. 2018 Aug 27;8(1):12868. doi: 10.1038/s41598-018-30325-9. Sci Rep. 2018. PMID: 30150711 Free PMC article.
-
Ethnicity and ERG frequency in prostate cancer.Nat Rev Urol. 2018 Feb;15(2):125-131. doi: 10.1038/nrurol.2017.140. Epub 2017 Sep 5. Nat Rev Urol. 2018. PMID: 28872154 Review.
-
Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence.Oncotarget. 2019 Nov 5;10(60):6466-6483. doi: 10.18632/oncotarget.27294. eCollection 2019 Nov 5. Oncotarget. 2019. PMID: 31741711 Free PMC article.
-
Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men.Biomedicines. 2023 May 9;11(5):1404. doi: 10.3390/biomedicines11051404. Biomedicines. 2023. PMID: 37239075 Free PMC article.
References
-
- American Cancer Society. Cancer facts & figures. Atlanta, GA: American Cancer Society; 2016.
-
- Hu Y, Dobi A, Sreenath T, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res. 2008;14:4719–25. - PubMed
-
- Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005;24:3847–52. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous